Anti-GAD65 antibodies are immunoglobulins that specifically recognize and bind GAD65, encoded by the GAD2 gene in humans. In research applications, these antibodies are used to detect GAD65 in tissue samples, cell lysates, and cultured cells. GAD65 catalyzes the synthesis of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and is concentrated at synaptic terminals, where it supports activity-dependent GABA production. Because GAD65 marks GABAergic neurons and is a major autoantigen in type 1 diabetes and stiff-person syndrome, it is studied across neuroscience and autoimmune disease research.
Catalog highlights and purchasing considerations
About the Biocompare GAD65 antibody catalog
The Biocompare antibody search tool lists GAD65 antibodies from a range of suppliers, with western blot, immunohistochemistry, and ELISA among the most common validated applications. Listings may also appear under the gene symbol GAD2 or combined with the related paralog GAD67/GAD1, reflecting the two isoforms' shared role in GABA synthesis. Several GAD65 antibodies mentioned here have been cited across a range of neuroscience research, including studies on scalable hypothalamic neuron differentiation from pluripotent stem cells for modeling metabolic disorders, combined fluorescent in situ hybridization and immunohistochemistry for mRNA co-localization in neurons, and memantine-mediated protection of motoneurons after spinal root lesion.
Considerations when choosing a GAD65 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.